1. Search Result
Search Result
Results for "

Proton Inhibitors

" in MedChemExpress (MCE) Product Catalog:

86

Inhibitors & Agonists

1

Screening Libraries

5

Fluorescent Dye

3

Peptides

2

Natural
Products

23

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15295
    Vonoprazan Fumarate
    4 Publications Verification

    TAK-438

    Proton Pump Metabolic Disease
    Vonoprazan Fumarate (TAK-438), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan Fumarate inhibits H +,K +-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan Fumarate is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease .
    Vonoprazan Fumarate
  • HY-100007
    Vonoprazan
    4 Publications Verification

    TAK-438 free base

    Proton Pump Bacterial Endocrinology
    Vonoprazan (TAK-438 free base), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan inhibits H +,K +-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. Vonoprazan can be used for eradication of Helicobacter pylori .
    Vonoprazan
  • HY-123754

    Proton Pump Inflammation/Immunology
    AGN-201904 is a proton pump inhibitor. AGN-201904 is an omeprazole prodrug that can delay aging and can be used to prevent and treat peptic ulcers .
    AGN-201904
  • HY-17507E

    Proton Pump Bacterial Infection
    S-Pantoprazole (sodium trihydrate) is related to Pantoprazole (HY-17507) that plays an important roles in gastric acid secretion disorder-related diseases, or as proton pump inhibitor .
    S-Pantoprazole sodium trihydrate
  • HY-100007A

    TAK-438 hydrochloride

    Proton Pump Bacterial Infection Endocrinology
    Vonoprazan hydrochloride, a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan hydrochloride inhibits H +,K +-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan hydrochloride is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. Vonoprazan hydrochloride can be used for eradication of Helicobacter pylori .
    Vonoprazan hydrochloride
  • HY-100007R

    TAK-438 (Standard)

    Proton Pump Bacterial Endocrinology
    Vonoprazan (Standard) is the analytical standard of Vonoprazan. This product is intended for research and analytical applications. Vonoprazan (TAK-438 free base), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan inhibits H +,K +-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. Vonoprazan can be used for eradication of Helicobacter pylori .
    Vonoprazan (Standard)
  • HY-G0007

    Omeprazole sulphone

    Drug Metabolite Infection Cancer
    Omeprazole sulfone is a metabolite of Omeprazole, which is a proton pump inhibitor.
    Omeprazole sulfone
  • HY-G0006

    Ufiprazole

    Drug Metabolite Others
    Omeprazole metabolite Omeprazole sulfide (Ufiprazole) is a metabolite of Omeprazole, which is a proton pump inhibitor.
    Omeprazole sulfide
  • HY-N6780

    Fungal Infection
    Ophiobolin B, a sesterterpene metabolite of Helminthosporium oryzae, inhibits proton extrusion from maize coleoptiles. Ophiobolin B inhibits fusicoccin (FC) promoted proton extrusion, potassium uptake and cell enlargement . The MIC values with the antifungal effect of Ophiobolins B on different zygomycetes is 25–50 μg/mL .
    Ophiobolin B
  • HY-17421A

    TU-199 sodium

    Proton Pump Cardiovascular Disease
    Tenatoprazole sodium (TU-199 sodium) is a proton pump inhibitor; inhibits hog gastric H +/K +-ATPase with an IC50 of 6.2 μM.
    Tenatoprazole sodium
  • HY-101646

    HOE-731

    Proton Pump Cardiovascular Disease
    Saviprazole is a Proton Pump inhibitor. Saviprazole can be used in research related to gastrointestinal diseases, such as gastric ulcers and acid reflux .
    Saviprazole
  • HY-100560S

    (S)​-​(+)​-​Abscisic acid-d6; ABA-d6

    Proton Pump Metabolic Disease
    Abscisic acid-d6 is deuterium labeled Abscisic acid. Abscisic acid inhibits proton pump (H+-ATPase)[1].
    Abscisic acid-d6
  • HY-13662S

    AG-1749-d4

    Proton Pump Bacterial Inflammation/Immunology Cancer
    Lansoprazole-d4 is a deuterium labeled Lansoprazole. Lansoprazole is a proton pump inhibitor which prevents the stomach from producing acid[1].
    Lansoprazole-d4
  • HY-141776S

    Ufiprazole-d3

    Drug Metabolite Others
    Omeprazole sulfide-d3 is the deuterium labeled Omeprazole sulfide. Omeprazole metabolite Omeprazole sulfide (Ufiprazole) is a metabolite of Omeprazole, which is a proton pump inhibitor.
    Omeprazole sulfide-d3
  • HY-121851

    SB 641257

    Proton Pump Inflammation/Immunology
    Revaprazan (SB 641257) is a reversible proton pump inhibitor with significant anti-inflammatory effects. Revaprazan can be used for chronic gastric inflammation research .
    Revaprazan
  • HY-100325

    Na+/H+ Exchanger (NHE) Neurological Disease
    NHE3-IN-1 is a sodium/proton exchanger type 3 (NHE-3) inhibitor extracted from patent WO 2011019784 A1.
    NHE3-IN-1
  • HY-G0007S

    Omeprazole sulfone-d3; Omeprazole sulphone-d3

    Isotope-Labeled Compounds Drug Metabolite Infection Cancer
    Omeprazole metabolite Omeprazole sulfone-d3 is the deuterium labeled Omeprazole metabolite Omeprazole sulfone. Omeprazole sulfone is a metabolite of Omeprazole, which is a proton pump inhibitor.
    Omeprazole sulfone-d3
  • HY-139557

    JP-1366

    Proton Pump Inflammation/Immunology
    Zastaprazan (JP-1366) is a proton pump inhibitor (WO2018008929). Zastaprazan can be used for the research of gastrointestinal inflammatory diseases or gastric acid-related diseases .
    Zastaprazan
  • HY-B0113S2

    Omeprazole sulfone (methoxy-d3); Omeprazole sulphone (methoxy-d3)

    Isotope-Labeled Compounds Drug Metabolite Infection Cancer
    Omeprazole metabolite Omeprazole sulfone (methoxy-d3) is the deuterium labeled Omeprazole metabolite Omeprazole sulfone. Omeprazole sulfone is a metabolite of Omeprazole, which is a proton pump inhibitor.
    Omeprazole metabolite Omeprazole sulfone (methoxy-d3)
  • HY-13662
    Lansoprazole
    1 Publications Verification

    AG-1749

    Proton Pump Bacterial Phospholipase Inflammation/Immunology Cancer
    Lansoprazole (AG 1749) is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) .
    Lansoprazole
  • HY-109546

    Proton Pump Metabolic Disease
    Omeprazole magnesium is an orally active proton pump inhibitor (PPI) and can suppress gastric acid. Omeprazole magnesium can be used for acid reflux-related symptoms and frequent heartburn research .
    Omeprazole magnesium
  • HY-161135

    Bacterial Infection
    TBAJ-5307 is a broad spectrum anti-non-tuberculous mycobacteria inhibitor that can target the FO-domain of the engine and preventing rotation and proton-translocation. TBAJ-5307 inhibits non-tuberculous mycobacteria in vitro and in vivo .
    TBAJ-5307
  • HY-13662B
    (R)-Lansoprazole
    2 Publications Verification

    Dexlansoprazole

    Proton Pump Inflammation/Immunology
    (R)-Lansoprazole is the R enantiomer of Lansoprazole, Lansoprazole (AG 1749) is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) .
    (R)-Lansoprazole
  • HY-148051

    Drug Metabolite Inflammation/Immunology Cancer
    Ilaprazole sulfone is the major metabolite of Ilaprazole (HY-101664), is predominantly catalysed by CYP3A4/5. Ilaprazole (IY-81149) is an orally active proton pump inhibitor .
    Ilaprazole sulfone
  • HY-109079A

    DWP14012 hydrochloride; Fexuprazan hydrochloride

    Proton Pump Metabolic Disease
    Abeprazan hydrochloride (DWP14012 hydrochloride) is a potassium-competitive acid blocker. Abeprazan hydrochloride inhibits H +, K +- ATPase by reversible potassium-competitive ionic binding with no acid activation required. Abeprazan hydrochloride is developed as a potential alternative to proton pump inhibitor for the treatment of acid-related diseases .
    Abeprazan hydrochloride
  • HY-109079

    DWP14012; Fexuprazan

    Proton Pump Metabolic Disease
    Abeprazan (DWP14012) is a potassium-competitive acid blocker. Abeprazan inhibits H +, K +- ATPase by reversible potassium-competitive ionic binding with no acid activation required. Abeprazan is developed as a potential alternative to proton pump inhibitor for the treatment of acid-related diseases .
    Abeprazan
  • HY-13662C

    Levolansoprazole

    Proton Pump Phospholipase Bacterial Inflammation/Immunology
    (S)-Lansoprazole (Levolansoprazole) is an isoform of Lansoprazole (HY-13662), which is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) .
    (S)-Lansoprazole
  • HY-17021B

    (S)-Omeprazole potassium salt; (-)-Omeprazole potassium salt

    Proton Pump Bacterial Inflammation/Immunology Endocrinology Cancer
    Esomeprazole potassium salt ((S)-Omeprazole potassium salt) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H +, K +-ATPase in gastric parietal cells. Esomeprazole potassium salt has the potential for symptomatic gastroesophageal reflux disease research .
    Esomeprazole potassium salt
  • HY-17021

    (S)-Omeprazole; (-)-Omeprazole

    Proton Pump Bacterial Inflammation/Immunology Endocrinology Cancer
    Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H +, K +-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .
    Esomeprazole
  • HY-W003467

    Proton Pump Bacterial Infection Inflammation/Immunology
    Rabeprazole Sulfide is an active metabolite of Rabeprazole. Rabeprazole is a proton pump inhibitor that suppresses gastric acid secretion through an interaction with (H +/K +)-ATPase in gastric parietal cells. Rabeprazole markedly inhibits the motility of H. pylori. Rabeprazole has the potential for various peptic diseases treatment .
    Rabeprazole Sulfide
  • HY-118283
    5-Hydroxylansoprazole
    1 Publications Verification

    AG1908

    Proton Pump Metabolic Disease
    5-Hydroxylansoprazole (AG1908) is an active metabolite of Lansoprazole in plasma. Lansoprazole is metabolized by CYP2C19 forming 5-Hydroxylansoprazole. Lansoprazole is a gastric proton-pump inhibitor and is effective in the treatment of various peptic diseases .
    5-Hydroxylansoprazole
  • HY-111036

    TRP Channel Others
    AMG0347 is a transient receptor potential type V1 receptor antagonist. AMG0347 inhibits activation of the rat TRPV1 channel by heat (IC50 = 0.2 nm), protons (IC50= 0.8 nm), or capsaicin (IC50 = 0.7 nm) .
    AMG0347
  • HY-137941

    Histamine Receptor Inflammation/Immunology
    Roxatidine is an active metabolite of Roxatidine acetate hydrochloride, is a histamine H2-receptor antagonist. Roxatidine, an anti-ulcer agent, suppresses histamine release (thus inhibiting proton secretion) and inhibits the production of VEGF-1, an important marker of inflammation and angiogenesis. Anti-allergic inflammatory effect .
    Roxatidine
  • HY-17021C

    (S)-Omeprazole hemistrontium; (-)-Omeprazole hemistrontium

    Proton Pump Bacterial Inflammation/Immunology Endocrinology Cancer
    Esomeprazole ((S)-Omeprazole) hemistrontium is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H +, K +-ATPase in gastric parietal cells. Esomeprazole hemistrontium has the potential for symptomatic gastroesophageal reflux disease research .
    Esomeprazole hemistrontium
  • HY-13662BS

    Dexlansoprazole-d4

    Isotope-Labeled Compounds Proton Pump Inflammation/Immunology
    (R)-Lansoprazole-d4 is deuterium labeled (R)-Lansoprazole. (R)-Lansoprazole is the R enantiomer of Lansoprazole, Lansoprazole (AG 1749) is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)[1][2].
    (R)-Lansoprazole-d4
  • HY-17021A

    (S)-Omeprazole magnesium salt; (-)-Omeprazole magnesium salt

    Proton Pump Bacterial Inflammation/Immunology Endocrinology Cancer
    Esomeprazole magnesium salt ((S)-Omeprazole magnesium salt) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H +, K +-ATPase in gastric parietal cells. Esomeprazole magnesium salt has the potential for symptomatic gastroesophageal reflux disease research .
    Esomeprazole magnesium salt
  • HY-B0656
    Rabeprazole
    2 Publications Verification

    LY307640

    Proton Pump Apoptosis Bacterial Inflammation/Immunology Cancer
    Rabeprazole (LY307640) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H +/K +-ATPase. Rabeprazole induces apoptosis. Rabeprazole acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC50 of 0.3 μM. Rabeprazole can be used for the research of gastric ulcerations and gastroesophageal reflux .
    Rabeprazole
  • HY-B0656A
    Rabeprazole sodium
    2 Publications Verification

    LY307640 sodium

    Proton Pump Apoptosis Bacterial Inflammation/Immunology Cancer
    Rabeprazole sodium (LY307640 sodium) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H +/K +-ATPase. Rabeprazole sodium induces apoptosis. Rabeprazole sodium acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC50 of 0.3 μM. Rabeprazole sodium can be used for the research of gastric ulcerations and gastroesophageal reflux .
    Rabeprazole sodium
  • HY-135111

    Drug Metabolite Infection Metabolic Disease Cancer
    4-Desmethoxy Omeprazole is the active metabolite of Omeprazole. Omeprazole, a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM . Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria .
    4-Desmethoxy Omeprazole
  • HY-B2145

    IY-81149 sodium

    Proton Pump TOPK Inflammation/Immunology Cancer
    Ilaprazole (IY-81149) sodium is an orally active proton pump inhibitor. Ilaprazole sodium irreversibly inhibits H +/K +-ATPase in a dose-dependent manner with an IC50 of 6 μM in rabbit parietal cell preparation. Ilaprazole sodium is used for the research of gastric ulcers. Ilaprazole sodium is also a potent TOPK (T-lymphokine-activated killer cell-originated protein kinase) inhibitor .
    Ilaprazole sodium
  • HY-B2145A

    IY-81149 sodium hydrate

    Proton Pump TOPK Inflammation/Immunology Cancer
    Ilaprazole (IY-81149) sodium hydrate is an orally active proton pump inhibitor. Ilaprazole sodium hydrate irreversibly inhibits H +/K +-ATPase in a dose-dependent manner with an IC50 of 6 μM in rabbit parietal cell preparation. Ilaprazole sodium hydrate is used for the research of gastric ulcers. Ilaprazole sodium hydrate is also a potent TOPK (T-lymphokine-activated killer cell-originated protein kinase) inhibitor .
    Ilaprazole sodium hydrate
  • HY-13662BR

    Proton Pump Inflammation/Immunology Cancer
    (R)-Lansoprazole (Standard) is the analytical standard of (R)-Lansoprazole. This product is intended for research and analytical applications. (R)-Lansoprazole is the R enantiomer of Lansoprazole, Lansoprazole (AG 1749) is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) .
    (R)-Lansoprazole (Standard)
  • HY-B0113S

    H 16868-d3

    Proton Pump Bacterial Autophagy Infection Metabolic Disease Cancer
    Omeprazole-d3 is deuterium labeled Omeprazole. Omeprazole, a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM[1]. Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria[2].
    Omeprazole-d<sub>3</sub>
  • HY-17023S

    (S)-Omeprazole-d6 sodium; (-)-Omeprazole-d6 sodium

    Isotope-Labeled Compounds Proton Pump Others
    Esomeprazole-d6 sodium is the deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H +, K +-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .
    Esomeprazole-d6 sodium
  • HY-B0113
    Omeprazole
    2 Publications Verification

    H 16868

    Proton Pump Autophagy Bacterial Phospholipase Infection Metabolic Disease Cancer
    Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM . Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria .Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) .
    Omeprazole
  • HY-B0113A
    Omeprazole sodium
    2 Publications Verification

    H 16868 sodium

    Proton Pump Autophagy Bacterial Phospholipase Infection Metabolic Disease Cancer
    Omeprazole sodium (H 16868 sodium), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole sodium shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM . Omeprazole sodium also inhibits growth of Gram-positive and Gram-negative bacteria . Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) .
    Omeprazole sodium
  • HY-17421

    TU-199

    Proton Pump Infection Inflammation/Immunology
    Tenatoprazole (TU-199) is an orally active imidazopyridine-based proton pump inhibitor with a prolonged plasma half-life. Tenatoprazole inhibits hog gastric H +/K +-ATPase activity with an IC50 of 6.2 μM. Tenatoprazole blocks the interaction of ubiquitin with the ESCRT-1 factor Tsg101, inhibits production of several enveloped viruses, including EBV .
    Tenatoprazole
  • HY-W013186S

    Proton Pump Bacterial Inflammation/Immunology
    Lansoprazole sulfide-d4 is a deuterium labeled Lansoprazole Sulfide. Lansoprazole Sulfide is an active metabolite of the proton pump inhibitor Lansoprazole. Lansoprazole Sulfide is an orally active anti-TB (Mycobacterium tuberculosis) agent with IC50 values of 0.59 µM intracellularly and 0.46 µM in broth[1].
    Lansoprazole sulfide-d4
  • HY-17021S

    (S)-Omeprazole-d3 sodium; (-)-Omeprazole-d3 sodium

    Isotope-Labeled Compounds Proton Pump Inflammation/Immunology Endocrinology Cancer
    Esomeprazole-d3 (sodium) is the deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research[1][2][3].
    Esomeprazole-d3 sodium
  • HY-17021S1

    (S)-Omeprazole-d3; (-)-Omeprazole-d3

    Isotope-Labeled Compounds Proton Pump Inflammation/Immunology Endocrinology Cancer
    Esomeprazole-d3 is deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research[1][2][3].
    Esomeprazole-d3

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: